Exploring chromone‐2‐carboxamide derivatives for triple‐negative breast cancer targeting EGFR, FGFR3, and VEGF pathways: Design, synthesis, and preclinical insights
Drug Development Research · 2024
DOI: 10.1002/ddr.22228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2024. Verfasst von Dalia S El-Gamil und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt. Hauptthemen laut MEDLINE: ErbB Receptors, Triple Negative Breast Neoplasms, Vascular Endothelial Growth Factor A, Antineoplastic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia.
Abstract (Originalsprache)
Chromone‐based compounds have established cytotoxic, antiproliferative, antimetastatic, and antiangiogenic effects on various cancer cell types via modulating different molecular targets. Herein, 17 novel chromone‐2‐carboxamide derivatives were synthesized and evaluated for their in vitro anticancer activity against 15 human cancer cell lines. Among the tested cell lines, MDA‐MB‐231, the triple‐negative breast cancer cell line, was found to be the most sensitive, where the N ‐(2‐furylmethylene) ( 15 ) and the α‐methylated N ‐benzyl ( 17 ) derivatives demonstrated the highest growth inhibition with GI 50 values of 14.8 and 17.1 μM, respectively. In vitro mechanistic studies confirmed the significant roles of compounds 15 and 17 in the induction of apoptosis and suppression of EGFR, FGFR3, and VEGF protein levels in MDA‐MB‐231 cancer cells. Moreover, compound 15 exerted cell cycle arrest at both the G0‐G1 and G2‐M phases. The in vivo efficacy of compound 15 as an antitumor agent was further investigated in female mice bearing Solid Ehrlich Carcinoma. Notably, administration of compound 15 resulted in a marked decrease in both tumor weight and volume, accompanied by improvements in biochemical, hematological, histological, and immunohistochemical parameters that verified the repression of both angiogenesis and inflammation as additional Anticancer mechanisms. Moreover, the binding interactions of compounds 15 and 17 within the binding sites of all three target receptors (EGFR, FGFR3, and VEGF) were clearly illustrated using molecular docking.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.
- Zoology Department, Molecular Physiology Division, Faculty of Science, Beni-Suef University, Beni Suef, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.
- Cancer Biology Department, Pharmacology Unit, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.
- Biochemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.
ORCID-Profile: Patrick M Maximous, Mohammad Abdel-Halim, Ahmed A Al-Karmalawy
Förderung
- Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia
Zitieren
APA
El-Gamil, D. S., Zaky, M. Y., Maximous, P. M., Sharaky, M., El-Dessouki, A. M., Riad, N. M., Shaaban, S., Abdel-Halim, M., & Al-Karmalawy, A. A. (2024). Exploring chromone‐2‐carboxamide derivatives for triple‐negative breast cancer targeting EGFR, FGFR3, and VEGF pathways: Design, synthesis, and preclinical insights. Drug Development Research. https://doi.org/10.1002/ddr.22228
Vancouver
El-Gamil DS, Zaky MY, Maximous PM, Sharaky M, El-Dessouki AM, Riad NM, et al. Exploring chromone‐2‐carboxamide derivatives for triple‐negative breast cancer targeting EGFR, FGFR3, and VEGF pathways: Design, synthesis, and preclinical insights. Drug Development Research. 2024. doi:10.1002/ddr.22228
BibTeX
@article{ElGamil2024,
author = {El-Gamil, Dalia S and Zaky, Mohamed Y and Maximous, Patrick M and Sharaky, Marwa and El-Dessouki, Ahmed M and Riad, Noura M and Shaaban, Saad and Abdel-Halim, Mohammad and Al-Karmalawy, Ahmed A},
title = {Exploring chromone‐2‐carboxamide derivatives for triple‐negative breast cancer targeting EGFR, FGFR3, and VEGF pathways: Design, synthesis, and preclinical insights},
journal = {Drug Development Research},
year = {2024},
doi = {10.1002/ddr.22228}
}
EUVIMED